NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tempus AI, Inc. (NASDAQ: TEM) resulting from allegations that Tempus AI may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Tempus AI securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tempus AI, Inc. (“Tempus” or “the Company”) (NASDAQ: TEM) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Tempus investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley ...

Editor’s note: This story has been updated to include a statement from a Tempus AI spokesperson.Spruce Point Capital Management has announced a new short position against Tempus AI Inc. TEM. On Wednesday, the short seller raised concerns about the company’s management team.What To Know: Tempus AI shares are tumbling Wednesday morning. Shortseller Spruce Point targeted the Chicago-based company in a new report titled “The Tempest Surrounding Tempus AI.”The firm blasted Tempus AI founder and CEO Eric Lefkofsk ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Tempus AI, Inc. following a critical report by Spruce Point Capital Management that raised concerns about the company's accounting practices and executive backgrounds [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is representing investors of Tempus AI, Inc. in an investigation regarding possible securities fraud and other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 2: Company Performance and Market Reaction - On May 28, 2025, Spruce Point Capital Management published a report highlighting concerns about Tempus, including aggressive accounting practices and the backgrounds of several board members linked to companies that have restated financial results [3]. - Following the release of the report, Tempus' stock price dropped by $12.67 per share, a decline of 19.23%, closing at $53.20 per share [3].

Shares of Tempus AI (TEM -18.41%) are falling on Wednesday. One of Cathie Wood's largest holdings, the company's stock plummeted 18.7% as of 2:15 p.m. ET. The collapse comes as the S&P 500 (^GSPC -0.09%) and the Nasdaq Composite (^IXIC 0.08%) were mostly flat.Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report from short-seller Spruce Point Capital Management that alleges the stock has as much as a 60% downside.Tempus ...

Spruce Point Capital Management has announced a new short position against Tempus AI Inc. TEM. On Wednesday, the short seller raised concerns about the company’s management team.What To Know: Tempus AI shares are tumbling Wednesday morning. Shortseller Spruce Point targeted the Chicago-based company in a new report titled “The Tempest Surrounding Tempus AI.”The firm blasted Tempus AI founder and CEO Eric Lefkofsky‘s past. Lefkofsky and his partner Brad Keywell, Spruce says, have a history of promoting disru ...

Group 1 - The article discusses the potential for investors to capitalize on undervalued stocks that are mispriced by the market as of the end of May [1] - It suggests that joining a specific investment service, Out Fox The Street, may provide insights on positioning in these stocks [1] Group 2 - There are no specific companies or stocks mentioned in the article, and the author discloses no current positions in any of the companies referenced [2][4] - The article emphasizes the importance of conducting personal research or consulting a financial advisor before making investment decisions [3][4]

I wanted to have a look at Tempus AI, Inc. ( NASDAQ: TEM ) which has seen some buzz recently, and see how it has performed recently, and what it is that it offers to the worldMSc in Finance. Long-term horizon investor mostly with 5-10 year horizon. I like to keep investing simple. I believe a portfolio should consist of a mix of growth, value, and dividend-paying stocks but usually end up looking for value more than anything. I also sell options from time to time.Analyst’s Disclosure: I/we have no stock, op ...

The primary goal of the Cash Flow Kingdom Income Portfolio is to produce an overall yield in the 7% - 10% range. We accomplish this by combining several different income streams to form an attractive, steady portfolio payout. The portfolio's price can fluctuate, but the income stream remains consistent. Start your free two-week trial today!Tempus AI, Inc. (NASDAQ: TEM ) is a healthcare tech player that has grown at a very nice pace in the past, including during the most recent quarter. The outlook for the r ...

Core Viewpoint - Tempus AI has shown significant growth and investor interest following its IPO, with a year-to-date stock increase of 91.8%, outperforming the Medical Info Systems industry and the broader market [1][2]. Financial Performance - In Q1 2025, Tempus AI reported a 75.4% year-over-year revenue increase and a 99.8% rise in gross profit [6]. - Genomics revenues grew by 89% year over year, with the core clinical diagnostics business expanding by 31% due to a 20% increase in volume [7]. - The company reported an adjusted EBITDA loss of $16.2 million, an improvement from a $43.9 million loss in the same period last year [8]. Strategic Partnerships and Initiatives - Tempus AI secured a $200 million, three-year deal with AstraZeneca and Pathos to develop a large oncology foundation model, increasing its total remaining contract value to over $1 billion [9]. - The acquisition of Ambry Genetics and the launch of the "olivia" personal health concierge app have enhanced the company's capabilities [10]. Revenue Guidance and Market Outlook - The company raised its full-year 2025 revenue outlook to $1.25 billion, indicating an 80% year-over-year growth, and expects a positive adjusted EBITDA of $5 million for the year [11]. - The recent executive order aimed at reducing U.S. drug prices could benefit Tempus AI by increasing demand for its AI-driven diagnostics and real-world data tools [12]. Valuation and Market Position - Despite recent gains, Tempus AI's stock is still 29.2% below its 52-week high, suggesting potential for further upward movement [13]. - The stock is currently trading at a forward price-to-sales ratio of 8.21, which is above the industry average of 6.0, indicating it may be slightly overvalued [14]. Investment Recommendation - Tempus AI is viewed as a "Hold" for now, with strong long-term potential but facing competition and currently trading at a premium [16].